Population pharmacokinetic analysis of 17-(allylamino)-17- demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies

Cancer Chemotherapy and Pharmacology

Volumn 55, Issue 3, 2005, Pages 237-243

  Chen, Xueyu ^a   Bies, Robert R ^b   Ramanathan, Ramesh K ^c,d   Zuhowski, Eleanor G ^c   Trump, Donald L ^c,d   Egorin, Merrill J ^c,d  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Geldanamycin; NONMEM; Population pharmacokinetics

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; ANTINEOPLASTIC AGENT; BILIRUBIN; BIOLOGICAL MARKER; CREATININE;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; BODY HEIGHT; BODY WEIGHT; CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DEMOGRAPHY; DRUG CLEARANCE; DRUG ELIMINATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LYMPHOMA; MALE; PHASE 1 CLINICAL TRIAL; PHYSICAL PERFORMANCE; POPULATION RESEARCH; PRIORITY JOURNAL;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; BENZOQUINONES; BIOLOGICAL MARKERS; BODY HEIGHT; BODY WEIGHT; FEMALE; HUMANS; LACTAMS, MACROCYCLIC; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASMS; RIFABUTIN; SEX FACTORS;

EID: 12444292077     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0836-8     Document Type: Article

References (24)

1. Aarons L, Karlsson MO, Mentre F, Rombout F, Steimer JL, van Peer A (2001) Role of modelling and simulation in phase I drug development. Eur J Pharm Sci 13:115
2. Akaike H (1979) A Bayesian extension of the minimal AIC procedures for autoregressive model fitting. Biometrika 66:237
3. Banerji U, O'Donnell A, Scurr M, Benson C, Hanwell J, Clark S, Raynaud F, Turner A, Walton M, Workman P, Judson I (2001) Phase I trial of heat shock protein 90 (HSP90) inhibitor 17-allylamino-17-demethoxygeldanamycin (17AAG): pharmacokinetic profile and pharmacodynamic endpoints (abstract). Proc Am Soc Clin Oncol 20:326
4. Bruno R (1999) http://www.cognigencorp.com/nonmem/nm/ 98jul021999.html, Accessed 13 March 2004
5. Bruno R, Hille D, Riva A, Vivier N, Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB (1998) Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16:187
6. Egorin MJ, Zuhowski EG, Rosen DM, Sentz DL, Covey JM, Eiseman JL (2001) Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17- demethoxygeldanamycin (NSC 330507) in CD2F1 micel. Cancer Chemother Pharmacol 47:291
7. Egorin MJ, Lagattuta TF, Hamburger DR, Covey JM, White KD, Musser SM, Eiseman JL (2002) Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother Pharmacol 49:7
8. Eisenhauer EA, OÆDwyer PJ, Christian M, Humphrey JS (2000) Phase I clinical trial design in cancer drug development. J Clin Oncol 18:684
9. Evans ND, Godfrey KR, Chapman MJ, Chappell MJ, Aarons L, Duffull SB (2001) An identifiability analysis of a parent-metabolite pharmacokinetic model for ivabradine. J Pharmacokinet Biopharm 28:93
10. Jonsson EN, Karlsson MO (1999) Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58:51
11. Karlsson MO, Beal SL, Sheiner LB (1995) Three new residual error models for population PK/PD analyses. J Pharmacokinet Biopharm 23:651
12. Karlsson MO, Jonsson EN, Wiltse CG, Wade JR (1998) Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. J Pharmacokinet Biopharm 26:207
13. Klein CE, Gupta E, Reid JM, Atherton PJ, Sloan JA, Pilot HC, Ratain MJ, Kastrissios H (2002) Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide. Clin Pharmacol Ther 72:638
14. Munster PN, Tong W, Schwartz L, Kenneson K, Cruz A, Rosen N, Scher H (2001) Phase 1 trial of 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) in patients wilh advanced solid malignancies (abstract). Proc Am Soc Clin Oncol 20:327
15. Munster PN, Marchion DC, Basso AD, Rosen N (2002) Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3′-kinase-AKT-dependent pathway. Cancer Res 62:3132
16. Nimmanapalli R, O'Bryan E, Bhalla K (2001) Geldanamycin and its analog 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res 61:1799
17. Ochel HJ, Eichhorn K, Gademann G (2001) Geldanamycin: the prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones. Cell Stress Chaperones 6:105
18. Scheibel T, Buchner J (1998) The Hsp90 complex - a superchaperone machine as a novel drug target. Biochem Pharmacol 56:675
19. Schnur RC, Corman ML, Gallaschun RJ, Cooper BA, Dee MF, Doty JL, Muzzi ML, Moyer JD, DiOrio CI, Barbacci EG (1995) Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J Med Chem 38:3806
20. Schoemaker RC, Cohen AF (1996) Estimating impossible curves using NONMEM. Br J Clin Pharmacol 42:283
21. Van Kesteren C, Mathot RA, Raymond E, Armand JP, Dittrich C, Dumez H, Roche H, Droz JP, Punt C, Ravic M, Wanders J, Beijnen JH, Fumoleau P, Schellens JH (2002) Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation. J Clin Oncol 20:4065
22. Williams PJ, Ette EI (2000) The role of population pharmacokinetics in drug development in light of the Food and Drug Administration's 'Guidance for Industry: population pharmacokinetics'. Clin Pharmacokinet 39:385
23. Wilson RH, Takimoto CH, Agnew EB, Morrison G, Grollman F, Thomas RR, Wasif Saif M, Hopkins J, Allegra C, Grochow LB, Szabo E, Hamilton JM, Monahan BP, Neckers L, Grem JL (2001) Phase I pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin (AAG) in adult patients with advanced solid tumors (abstract). Proc Am Soc Clin Oncol 20:325
24. Xu L, Eiseman JL, Egorin MJ, D'Argenio DZ (2003) Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17- demethoxygeldanamycin and its active metabolite in tumor-bearing mice. J Pharmacokinet Pharmacodyn 30:185